Two products say 2% salicylic acid: what actually matches?

CoreAge advertises a four-ingredient Pore Favor preparation. Its current offer lists salicylic acid 2%, niacinamide 8%, zinc oxide 5% and urea 2%. The product page calls it a compounded cream. Those are the company's descriptions of its offer, not results from our analysis of a dispensed sample. CoreAge product page Current offer

The Ordinary's exact US product is a water-based solution, while CeraVe's Acne Control Cleanser is a cleansing gel-to-foam product. Both name 2% salicylic acid, but neither name refers to the CoreAge mixture. CeraVe manufacturer record Our formula review keeps the advertised combination separate from the other finished products.

FDA's Drug Facts guide treats the active ingredient, purpose, uses, warnings, directions and inactive ingredients as separate parts of an OTC record. Reading one field does not make the others unnecessary. A strength declaration does not identify every component that surrounds the active ingredient or every condition described on the package. FDA label explanation

That distinction is especially useful when comparing a product with a published ingredient panel and an offer that names selected ingredients. Pore Favor's public pages do not establish the entire base of an individual supplied preparation. The absence of that information cannot be filled by borrowing the inactive list of a retail product with the same active percentage.

The Ordinary describes its solution as a water-based acne serum intended to remain on the skin. CeraVe identifies its exact cleanser as a wash, and the corresponding label includes rinsing among its directions. These records establish different product roles. The Ordinary product record CeraVe labeling

They do not provide a method for calculating equivalent exposure between a cream, solution and cleanser. Nor can a reader infer which must work faster or irritate less from the format alone. The retail and compounded categories guide adds another distinction: a format description and a regulatory pathway answer different questions.

AAD includes salicylic acid in its adult-acne guidance, particularly in the discussion of blackheads and whiteheads. That gives context for why acne products may include it. It does not establish that every product with the same percentage produces the same result in every person. AAD adult-acne guidance

A comparison of outcomes would need to identify the complete products, the people studied and the actual measures used. A pleasant skin feel, fewer blemishes and a change in visible shine are not automatically interchangeable endpoints. None of the three public product records reviewed here establishes a direct clinical comparison between all three preparations for those outcomes.

The cleanser and solution describe ingredients or benefits that may sound reassuring, but their records also contain irritation and dryness warnings. AAD discusses those concerns with salicylic-acid acne treatment more generally. That context deserves to remain visible rather than being overridden by a longer ingredient list. AAD moisturizer discussion

The CeraVe label review and Ordinary review examine the exact records. The Ordinary page's different frequency wording in its usage panel and FAQ is not reconciled here into a schedule. A same-percentage comparison cannot resolve instructions that need clarification for the particular product.

The ingredient percentage does not reveal how much product is in an order. A bottle's net contents and a provider's plan description are separate from its concentration. CoreAge's plans are described in months, while retail records can describe individual containers. Those terms cannot simply be placed on one price-per-treatment scale.

The year-plan cost guide examines what is known about the commercial term and what remains uncertain about quantity. It does not calculate use amounts or how long a preparation should be used. A lower displayed number may answer a pricing question only after the actual unit of sale is established.

The supported observation is that the reviewed records share a stated salicylic-acid percentage. Equal finished-product performance, matching instructions, identical tolerability and suitability for the same person do not follow from that observation. The comparison becomes more useful when those remaining questions are named rather than hidden behind the matching number.

The fixed comparison records reader presents strength alongside identity, regulatory context and supply terms. Our commercially disclosed shortlist uses the same boundaries. Neither page authorizes switching products or assigns a clinical winner. A qualified professional can interpret the exact records in the context of an actual treatment discussion.